FDA OK's Regeneron's Eylea in diabetic retinopathy
Regeneron Pharmaceuticals' Eylea (aflibercept) won the FDA's approval on 25 March as a treatment for diabetic retinopathy in patients with diabetic macular edema (DME).
Regeneron Pharmaceuticals' Eylea (aflibercept) won the FDA's approval on 25 March as a treatment for diabetic retinopathy in patients with diabetic macular edema (DME).